Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 14/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7075284 | 0.99 | ELANE (0.48) | ELANECYP1A2CYP2D6MAPTKMT2A | |
| SCHEMBL7956686 | 0.82 | ELANE (0.48) | ELANECYP1A2CYP2D6MAPTKMT2A | |
| SCHEMBL6804849 | 0.80 | ELANE (0.39) | ELANE | |
| SCHEMBL27158525 | 0.80 | PTPN1 (0.46) | ELANEMAPTKMT2AAPLNR | |
| Hydrochloric Acid SCHEMBL6806816 | 0.79 | ELANE (0.39) | ELANE | |
| Hydrochloric Acid SCHEMBL7129582 | 0.79 | ELANE (0.39) | ELANE | |
| Hydrochloric Acid SCHEMBL7125040 | 0.78 | ELANE (0.51) | ELANEMAPTKMT2AKIF11 | |
| SCHEMBL7071124 | 0.77 | ELANE (0.54) | ELANEMAPT | |
| Hydrochloric Acid SCHEMBL7125586 | 0.74 | PTPN1 (0.55) | ELANEMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL7125581 | 0.74 | PTPN1 (0.55) | ELANEMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO., LTD. | 2003-08-14 | — | — | US | claimed |
| US-6534658-B1 | Intermediates for producing pharmaceuticals | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | claimed |
| EP-1162199-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | OXA1L, CYP1B1, OXER1 | ELANE 4189/4885CYP1A2 8/4885CYP2D6 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.